# A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer

Source: https://onco.cc/trials/nct07450976/  
OnCo record `nct07450976` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of SHR-A1904 for Injection in biliary tract cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.

## Summary

A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer is a phase 2 interventional study registered as NCT07450976 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 151 participants planned, started 2026-03-25 and due to reach its primary completion in 2030-12. Interventions recorded: SHR-A1904 for Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07450976
- Phase: 2
- Setting: A Phase IIa/IIb Clinical Study of SHR-A1904 in Patients With Previous Systemic Treatment Failure, Positive CLDN18.2 Expression of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
- Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Enrolled: 151

## Sources

- ClinicalTrials.gov NCT07450976: https://clinicaltrials.gov/study/NCT07450976

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07450976.json